ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • ASLAN Pharmaceuticals (NASDAQ:ASLNhas closed a secured loan facility provided by K2 HealthVentures (K2HV). 
  • Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing consisting of a $20 million initial term loan funded at closing, with the remaining $25 million subject to specific terms and conditions.
  • Proceeds will be used to advance the clinical development of ASLAN003 in autoimmune gastrointestinal and skin diseases and general corporate purposes. 
  • ASLAN expects to initiate a Phase 2 clinical trial for ASLAN003 in inflammatory bowel disease in early 2022.
  • Price Action: ASLN shares are down 0.32% at 3.11 during the premarket session on the last check Tuesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksHealth CareFinancingGeneralBriefs